North America Capecitabine Market

North America Capecitabine Market Size & Growth (2023 to 2028): 

The size of the North America Capecitabine Market is anticipated to grow with a healthy CAGR during the forecast period ie from 2023 to 2028

The rising demand for Capecitabine can be attributed to its antimetabolite action, which operates by interfering with DNA synthesis and lowering the severity of side effects. In addition, Capecitabine has been effective and well-tolerated in breast cancer patients when combined with taxane-based chemotherapy drugs like docetaxel (Taxotere) and paclitaxel (Taxol).

As a result, the rising burden of breast cancer and expanding patient awareness of the benefits are projected to drive North American market expansion. In addition, the surge in cancer cases and the patent expiration of Capecitabine have boosted the demand for Capecitabine.

Furthermore, continuous capecitabine research initiatives and a favorable regulatory environment are positive indicators for capecitabine medication demand. The capecitabine market is expected to develop as the prevalence of cancer rises, demand for target medication therapy rises, and Capecitabine's patent expires.

According to the National Cancer Institute, around 135,460 persons in the United States were diagnosed with colon and rectum cancer in 2017, with 50,269 people dying from the disease. Furthermore, rising healthcare expenditures and increased government and private sector investment in cancer treatment or assistance programs such as Cancer Care and Cancer Suraksha Scheme are expected to drive North America's capecitabine market expansion.

Due to severe side effects connected with Capecitabine, the North American capecitabine market is significantly restricted. In addition, the high cost of Capecitabine, the availability of competitors such as raltitrexed and leucovorin, and government rules governing Capecitabine's safety and efficacy all stymie North America capecitabine market expansion.

This research report on the North America Capecitabine Market has been segmented and sub-segmented into the following categories.

By Application: 

• Colon Cancer
• Rectal Cancer
• Breast Cancer
• Gastric Cancer
• Others

By Drug Formulation:

• Tablets
• Capsules

By Country:

• U.S
• Canada
• Rest of North America

Geographically, North America is estimated to lead the global capecitabine market due to the increased government funding for cancer research; the rising prevalence of different types of cancers in the region, such as breast cancer and colorectal cancer, are expected to fuel the growth of the North America Capecitabine Market.

The U.S Capecitabine Market is predicted to reach a decent CAGR because of the rising incidence of unhealthy lifestyle-induced diseases during the forecast period. Furthermore, a sharp increase in the older population in the United States due to baby boomers led to increased revenue for the region. According to the International Diabetes Federation, over 48 million persons in North America will have diabetes in 2019. More than half of the patients will be over 65, and this trend is likely to continue.

The Canada Capecitabine Market is projected to grow significantly due to increased cancer cases. In addition, physical inactivity, obesity, stress, and a sedentary lifestyle can increase market growth.

KEY MARKET PLAYERS

Companies playing a dominant role in the North America Capecitabine Market profiled in this report are Novartis AG, Sensus Healthcare, RXi Pharmaceuticals, Inc., Revitol Corporation and Avita Medical Limited, Sonoma Pharmaceuticals, Inc., Perrigo Company plc, Bristol-Myers Squibb Company, Valeant Pharmaceuticals International, Inc, Pacific World Corporation.,